Phase 3 Study Evaluating Ravulizumab for COVID-19 Paused
The open-label, controlled study enrolled adults hospitalized with COVID-19 and severe pneumonia, acute lung injury or acute respiratory distress syndrome.
The open-label, controlled study enrolled adults hospitalized with COVID-19 and severe pneumonia, acute lung injury or acute respiratory distress syndrome.
47 percent experience fatigue, with no correlation between any measures of persistent disease and initial disease severity
TMB-003 is a locally delivered formulation of sitaxsentan, a highly selective endothelin receptor antagonist.
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
Early administration of high-titer convalescent plasma against SARS-CoV-2 reduces progression in mildly ill older adults
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
The full list of CFTR gene mutations for Trikafta, Symdeko and Kalydeco can be found in the updated prescribing information for each respective product.
The global, double-blind, placebo-controlled RUXCOVID study compared ruxolitinib to placebo, in addition to standard of care, in 432 patients aged 12 years and older with COVID-19 associated cytokine storm.